Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.

Original reporting
Published Oct 28, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 11:22 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss — source image
Decision brief

The 30-second read

$REPLBullishMed
01

Why it matters

The earnings report provides fresh financial data that could influence short‑term trading decisions.

02

Market read

Primary earnings disclosure for a small‑cap biotech, offering new data for traders.

03

What to watch

Cash burn and upcoming trial expenses could offset short‑term optimism.

Relevance 7/10Novelty 8/10Timing: after-hours

Background

Quarterly earnings release for Replimune Group, Inc. (REPL).

Company-level read

Ticker impact

$REPLBullishHigh confidence
Context

Replimune reported Q2 2027 results with a net loss of $57.1M and cash of $307.8M.

Expected impact

potential modest upside as loss narrowed year‑over‑year

Evidence & confidence

The reduction in net loss suggests improving operations, likely attracting buying interest.

Market effects

Biotech sector may see slight positive sentiment from improved loss metrics.

U.S. biotech investors could adjust positions based on the earnings beat.

Limited to niche oncology investors; no broad market effect.

Counterpoint

Loss remains substantial; investors may remain cautious despite narrowing.

Key entities

  • Replimune Group, Inc.

    Biotech firm reporting Q2 results.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune Group, Inc. (REPL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m.